Faculty profile

Glenwood Goss

Back to faculty

Full ProfessorDepartment of MedicineUniversity of Ottawa

Glenwood Goss

Full Professor

Department of Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
2 publications in the last five years, latest in 2025.
Principal investigator on 1 research grant (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

1,360

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Biotherapeutics Extracellular Vesicles Hard To Treat Cancers Sting Pathway

Latest papers

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
Therapeutic Advances in Medical Oncology · 2025 · first author
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nature medicine · 2024
Novel Nanoparticle-Based Cancer Treatment, Effectively Inhibits Lung Metastases and Improves Survival in a Murine Breast Cancer Model.
Frontiers in oncology · 2021

All 27 publications

Latest funding

Engineered Extracellular Vesicles to Enhance Immunotherapy in Immunosuppressive Non-Small Cell Lung Cancers
CIHR · 2024 · Principal investigator
$933,300
New Oral Anticoagulants for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
CIHR · 2012 · Co-investigator
$836,840

All 2 grants and awards

27 publications.

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Goss G, Ciuleanu T, Ramlau R, Renouf DJ, Chu Q, Kalinka E, Sawrycki P, Bramson J, Nelson BH, Crabbé R

Therapeutic Advances in Medical Oncology20251 citationsFirst author

DOI: 10.1177/17588359251332154

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV

Nature medicine2024

DOI: 10.1038/s41591-024-02808-y PMID: 38351187

Novel Nanoparticle-Based Cancer Treatment, Effectively Inhibits Lung Metastases and Improves Survival in a Murine Breast Cancer Model.

Kraus S, Khandadash R, Hof R, Nyska A, Sigalov E, Eltanani M, Rukenstein P, Rabinovitz R, Kassem R, Antebi A, Shalev O, Cohen-Erner M, Goss G, Cyjon A

Frontiers in oncology2021

DOI: 10.3389/fonc.2021.761045 PMID: 34804962

A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

Stewart DJ, Bossé D, Goss G, Hilton JF, Jonker D, Fung-Kee-Fung M

Critical reviews in oncology/hematology2020

DOI: 10.1016/j.critrevonc.2020.102896 PMID: 32087510

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Kuruvilla P, Hill D, El-Maraghi R, Witham D, Abou-Nassar K, Schattner A, Spadafora S, Marquis K, Trinkaus M, Mallick R

New England Journal of Medicine2019848 citations

DOI: 10.1056/nejmoa1814468

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219

Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA

Lung Cancer201928 citations

DOI: 10.1016/j.lungcan.2019.04.027

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G

Cancer2019Senior author

DOI: 10.1002/cncr.31891 PMID: 30512189

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).

Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019

DOI: 10.1016/j.jtho.2019.05.010 PMID: 31121324

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

Gotfrit J, Jonker C, Zhang T, Goss G, Nicholas G, Laurie S, Wheatley-Price P

Cancer treatment and research communications2019

DOI: 10.1016/j.ctarc.2019.100130 PMID: 30927666

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C

Lung Cancer201856 citations

DOI: 10.1016/j.lungcan.2018.03.005

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Biotherapeutics Dear Professor Goss, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study" (2025), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Engineered Extracellular Vesicles to Enhance Immunotherapy in Immunosuppressive Non-Small Cell Lung Cancers" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Glenwood Goss

Research

Latest papers

Latest funding

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Novel Nanoparticle-Based Cancer Treatment, Effectively Inhibits Lung Metastases and Improves Survival in a Murine Breast Cancer Model.

A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70&#xa0;Years&#xa0;or Older or with Poor Performance Status (CheckMate 153).

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

Engineered Extracellular Vesicles to Enhance Immunotherapy in Immunosuppressive Non-Small Cell Lung Cancers

New Oral Anticoagulants for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Frequent collaborators

John Goffin

Paul Wheatley-Price

Lesley Seymour

Geoffrey Liu

Ming-Sound Tsao

Jim Dimitroulakos

Wei Xu

Stephen Lam

Sevtap Savas

Sonya Cressman

Ashish Gupta

Bryan Lo

David Stewart

Derek Jonker

Jean Seely

Kayvan Amjadi

Michael Fung-Kee-Fung

Timothy Ramsay

Alejandro Lazo-Langner

Andrew Arnold

William Evans

Vicky Tagalakis

Marc Rodger

Marc Rodger

Elizabeth Kurien

Kazuhiro Yasufuku

Rayjean Hung

Sudeep Shivakumar

Marc Carrier

Grégoire Le Gal

Stuart Peacock

Glenwood Goss

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).